Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhBMP-2/ACS for Dental Implant Stability
NCT05719181Phase 1Unknown
- Sponsor
- University of Baghdad
- Start
- Dec 2021
- Primary completion
- Mar 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised trial of dibotermin alfa in Alveolar bone loss (2 arms), sponsored by University of Baghdad. Primary endpoint: Secondary stability of dental implant. Status: unknown.
02
Drugs
dibotermin alfa
03
Conditions
Alveolar bone loss
Beyond the preview
Go deeper on NCT05719181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05719181.